At Biovotec we are working to shape the future of wound healing. By reducing the cost of advance wound care products, we offer an unrivaled advantage for both patients and clinicians. We believe that everybody should have access to affordable, advance wound care products. Generally the body has an amazing ability to heal itself. However, under some circumstances ulcers may form and wounds may heal slowly, becoming chronic. In these cases extensive treatment and medication are required and with a significantly increased healing time. In the worst cases healing times extend to several years and some may never truly heal. Biovotec is developing a series of next-generation, advanced wound care products based on a novel biomaterial derived from hen eggshell membrane. Thanks to a novel separation and purification process - exclusively available to Biovotec – functional biomaterials can now be produced based on native, unmodified eggshell membrane.
Looking for a particular Biovotec employee's phone or email?
The Biovotec annual revenue was $4 million in 2026.
Henri-Pierre Suso is the Co founder and CTO at Biovotec of Biovotec.
1 people are employed at Biovotec.
Biovotec is based in Oslo, Oslo.
The NAICS codes for Biovotec are [54171, 541, 541713, 54, 5417].
The SIC codes for Biovotec are [87, 873].